Patients with genital herpes were treated three times weekly for 12 weeks with 3 x 106 IU of alpha2b interferon (20 patients) or placebo (17 patients) administered by subcutaneous injection in a double-blind trial. Interferon had minimal effects on the suppression of recurrences and moderate toxicity (chills, fever, fatigue, and leukopenia), suggesting that this route and dosage of interferon may not be clinically useful for this indication.
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Genital herpes establishes latency in the sacral nerve following a primary attack and recurs in 80 to 90% of patients (1) . Attempts to prevent these recurrences with daily administration of oral acyclovir have been successful. However, this drug is not curative, so that when therapy is terminated, the outbreaks recur at their original frequency (2, 11) . In addition, the possibility of the emergence of acyclovirresistant viruses has prompted the search for other antiviral agents effective for this indication.
Human alpha interferon possesses antiviral and immuneenhancing properties. Its availability in large quantities owing to recombinant genetic technology has allowed clinical trials to test its usefulness in the therapy of genital herpes. However, it proved to be ineffective in shortening the duration of virus shedding or the time of healing of a recurrence when compared with a placebo (3). We hoped that it might be effective in genital herpes when used prophylactically to prevent recurrences, as it prevented the reactivation of herpes simplex after sectioning of the trigeminal root (9) , reactivation of cytomegalovirus in transplant recipients (6) , and transmission of rhinovirus (4) . Therefore, we undertook a placebo-controlled, double-blind evaluation of recombinant alpha2b interferon in the prevention of frequent recurrences of genital herpes.
( the placebo group (P = 0.87). There were no differences between the two groups if results were analyzed at the end of week 4 or 8. The numbers of patients who remained free of recurrences during therapy were 3 of 18 interferon recipients and 0 of 17 placebo recipients (P = 0.23). In the 25 weeks following the conclusion of therapy, the mean numbers of recurrences were 3.2 and 4.0, respectively (P = 0.84). All three of the interferon-treated patients who were free of recurrences during therapy suffered recurrences at 1 week (two patients) and 15 weeks (one patient) following the cessation of therapy.
Therapy was discontinued in only two cases because of severe side effects (fever and chills). The remainder of adverse reactions were either mild or moderate. The main symptoms reported in interferon recipients were chills, fever, and fatigue, while placebo recipients reported only fatigue (P < 0.01) ( Table 3) . Signs indicating central nervous system toxicity were depression and somnolence in interferon recipients. There were seven cases of leukopenia in the interferon group. The mean leukocyte count for these seven was 3,500/mm3 at the nadir. The nadirs were reached at the end of week 1 of therapy (two cases), at the end of week 8 (two cases), and at the end of week 12 (three cases). There were no cases of leukopenia in the placebo group. No incidences of thrombocytopenia, interferon-neutralizing factors, or any significant abnormalities of blood chemistries or urinalyses were noted in either group.
In this study, we observed no significant effect of interferon in comparison with the placebo on the duration of virus shedding or on the rate of healing of the first recurrence. These results appeared very similar to those of our previous study (3) , in which we noted mean durations of healing of 6.4 days in interferon recipients and 5.8 days in placebo recipi- (9) demonstrating the prevention by interferon of the reactivation of virus following sectioning of the trigeminal nerve. While it is possible that with larger numbers a statistically significant effect of interferon may be demonstrable, in view of its toxicity it appears unlikely that this type of interferon (alpha2b), dosage schedule, or route of administration will have a therapeutic or suppressive role in genital herpes. However, we are using topical routes of administration to reduce toxicity and combining interferon with other antiviral agents which show in vitro synergy with interferon (5, 8 ) to attempt to demonstrate a clinically useful effect in patients with genital herpes.
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